Targeting TKI-Activated NFKB2-MIF/CXCLs-CXCR2 Signaling Pathways in FLT3 Mutated Acute Myeloid Leukemia Reduced Blast Viability

Disease relapse is a common cause of treatment failure in FMS-like tyrosine kinase 3 (FLT3) mutated acute myeloid leukemia (AML). In this study, to identify therapeutic targets responsible for the survival and proliferation of leukemic cells (blasts) with FLT3 mutations after gilteritinib (GILT, a 2...

Descrición completa

Detalles Bibliográficos

Principais autores:	Huynh Cao, Verena Tadros, Benjamin Hiramoto, Kevin Leeper, Christopher Hino, Jeffrey Xiao, Bryan Pham, Do Hyun Kim, Mark E. Reeves, Chien-Shing Chen, Jiang F. Zhong, Ke K. Zhang, Linglin Xie, Samiksha Wasnik, David J. Baylink, Yi Xu
Formato:	Artigo
Idioma:	Inglês
Publicado:	MDPI AG 2022-04-01
Series:	Biomedicines
Assuntos:	AML FLT3 NFKB2 CXCR2 MIF gilteritinib
Acceso en liña:	https://www.mdpi.com/2227-9059/10/5/1038
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!